DNA Script expands access to on-demand DNA synthesis in India through distributor agreement with Imperial Life Sciences

DNA Script, the programmable biology company developing next-generation enzymatic DNA synthesis (EDS) technologies, has announced a new distribution agreement with Gurugram-based Imperial Life Sciences (ILS), expanding access to the company's SYNTAX^® platform across India.

Under the agreement, ILS will distribute DNA Script's SYNTAX platform throughout the country, providing local sales, technical support and application expertise to researchers seeking faster, more flexible access to high-quality single-stranded DNA (ssDNA) oligonucleotides.

The agreement with ILS builds on DNA Script’s recent expansion of its global distribution network across Latin America and East Asia, extending the availability of the SYNTAX platform into another key growth market for life sciences research. The partnership supports the company’s strategy to broaden adoption of decentralized, on-demand DNA synthesis and strengthen access to DNA production capabilities in rapidly growing research ecosystems.

By shifting DNA production from centralised manufacturing facilities to the laboratory bench, researchers gain greater control over workflows, faster turnaround times and reduced dependence on complex supply chains.

The SYNTAX platform combines DNA synthesis, purification and normalisation in a single automated workflow, allowing laboratories to produce up to 384 oligonucleotides in parallel and accelerate design-build-test cycles across a wide range of research applications.